Jaffetilchin Investment Partners LLC Has $757,000 Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Jaffetilchin Investment Partners LLC trimmed its position in Zoetis Inc. (NYSE:ZTS) by 1.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,874 shares of the company’s stock after selling 75 shares during the quarter. Jaffetilchin Investment Partners LLC’s holdings in Zoetis were worth $757,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. Vanguard Group Inc. increased its stake in shares of Zoetis by 1.0% in the first quarter. Vanguard Group Inc. now owns 40,749,571 shares of the company’s stock worth $6,895,235,000 after purchasing an additional 414,605 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Zoetis by 4.0% during the second quarter. Bank of New York Mellon Corp now owns 4,687,902 shares of the company’s stock worth $812,695,000 after buying an additional 178,303 shares during the last quarter. Capital Research Global Investors boosted its position in shares of Zoetis by 2.3% in the first quarter. Capital Research Global Investors now owns 4,050,681 shares of the company’s stock valued at $685,416,000 after acquiring an additional 90,330 shares during the period. Clearbridge Investments LLC increased its position in Zoetis by 5.8% during the second quarter. Clearbridge Investments LLC now owns 3,044,384 shares of the company’s stock worth $527,774,000 after acquiring an additional 166,517 shares during the period. Finally, Principal Financial Group Inc. raised its stake in Zoetis by 17.3% during the 3rd quarter. Principal Financial Group Inc. now owns 2,377,403 shares of the company’s stock valued at $464,497,000 after purchasing an additional 351,372 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Down 0.4 %

ZTS opened at $176.16 on Tuesday. The firm has a market cap of $79.48 billion, a price-to-earnings ratio of 33.11, a PEG ratio of 2.71 and a beta of 0.90. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.09 and a current ratio of 3.69. The firm’s 50-day simple moving average is $188.15 and its 200-day simple moving average is $179.77. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.46 by $0.12. The company had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company’s revenue was up 11.6% on a year-over-year basis. During the same quarter last year, the business posted $1.36 earnings per share. Equities research analysts anticipate that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be issued a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a dividend yield of 0.98%. The ex-dividend date is Thursday, October 31st. Zoetis’s payout ratio is presently 32.33%.

Analysts Set New Price Targets

Several research firms have issued reports on ZTS. JPMorgan Chase & Co. raised their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Piper Sandler upped their price target on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Stifel Nicolaus upped their target price on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Finally, BTIG Research raised their target price on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.